NewswireToday - /newswire/ -
Irvine, CA, United States, 2013/02/18 - MDxHealth SA announced the results of two studies of the ConfirmMDx™ for Prostate Cancer test presented at the ASCO Genitourinary Cancers Symposium 2013, February 14-16, Orlando, Florida, USA. NYSE Euronext: MDXH
MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced the results of two studies of the ConfirmMDx™ for Prostate Cancer test presented at the ASCO Genitourinary Cancers Symposium 2013, February 14-16, Orlando, Florida, USA.
"These additional clinical studies add to our extensive body of peer-reviewed evidence, clearly demonstrating the ability of ConfirmMDx for Prostate Cancer test to provide valuable diagnostic information to support urologists in better patient management," said Jesse Savala, M.D., clinical pathologist and Medical Director at MDxHealth. "With the advances being made in human epigenetics, we believe that DNA methylation-based tests hold the promise to improve the diagnosis and subsequent treatment of cancer patients."
Studies clearly show that the ConfirmMDx™ for Prostate Cancer test provides very important personalized information that cannot be achieved with traditional procedures:
• In the Epigenetic Field Effect study in Histologically Benign Prostate Biopsy Cores it was shown that GSTP1, APC and/or RASSF1 gene promoter methylation is more prevalent in histologically benign cores from prostate cancer (PCa) patients diagnosed with Gleason Score (GS) 7 PCa, as compared with low volume GS 6. This study confirms previous findings in a larger cohort of subjects that these "field effect" biomarkers can be useful for detecting cancer adjacent to histologically negative biopsies and may be indicative of occult aggressive PCa.
• The multi-gene ConfirmMDx™ for Prostate Cancer test demonstrated that epigenetic profiling is a significant predictor for PCa risk, especially to identify those men who should (not) undergo a repeat biopsy following a negative initial biopsy. An integrated risk management approach that combines this epigenetic assay with other risk factors, most notably histopathologic features of the cancer-negative initial biopsy, resulted in an improved prediction for the presence of PCa with sensitivity and negative predictive values of respectively 74% and 91%.
About ConfirmMDx for Prostate Cancer
Over 650,000 American men receive a negative prostate biopsy result each year; though approximately25% of these men may still harbor occult prostate cancer. This well-documented risk of undetected cancer, often with clinically significant disease leads to a high rate of repeat biopsies with over 40% of men receiving at least one repeat biopsy, and many receiving a 3rd and 4th biopsy. Today's gold standard diagnostic approach is the prostate biopsy procedure, collecting 10-12 needle core biopsy samples, however this sampling represents less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is an epigenetic assay to help urologists distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test is able to detect an epigenetic field effect or "halo" resulting from oncogenic processes at the DNA level in cells adjacent to cancer foci. This molecular "halo" around a cancer lesion can be present despite having a normal appearance under the microscope. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment.
MDxHealth (mdxhealth.com) is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, the ConfirmMDx™ for Prostate Cancer test, has been shown to help distinguish patients who have a true-negative biopsy from those who may have occult cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium.
Mike Sinclair, Halsin Partners
T: +44 20 7318 2955 / C: +44 7968 022075 - E: msinclair[.]halsin.com.
Seth Lewis, The Trout Group
T: +1 646 378 2952 - E: slewis[.]troutgroup.com.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.